In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Katz, Founder & CSO at Sparrow Pharmaceuticals, Inc.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:
The contrast of developing new drugs and running clinical trials in a big pharma versus his journey as the founder of a virtual biopharma company.
What life really looks like and skills you have to develop in a firm developing novel, targeted therapies to address unmet patient needs.
Some of the options, decisions and pathways to commercialization that a Phase 2 biopharma business has to consider.
The inspiration, leadership learnings and brand influence of a famous Hollywood character.
Prior to founding Sparrow, David was a pharmaceutical R&D leader at Abbott and AbbVie, where he led clinical development and drug discovery teams, and was a personalized medicine pioneer. David is dedicated to the mentorship of the next generation of life sciences entrepreneurs, currently as an entrepreneur-in-residence at Oregon Health & Science University. He held post-doctoral fellowships in immunology at the Universities of Chicago and Michigan, earned MPhil and PhD degrees in Molecular Biophysics and Biochemistry from Yale University, and is an alumnus of Pomona College (BA, Chemistry). David has published over 50 peer-reviewed scientific papers and in his copious spare time, he is actively involved in new play development and is a glass artist.
Don’t forget to subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.